Senator Rick Scott called for a comprehensive review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approval processes.
Call for a comprehensive review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approval processes.
Occurrences
Senator Rick Scott sent a letter to the Department of Health and Human Services, National Institutes of Health, and Food and Drug Administration, urging a review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approvals.
Evidence
On March 19, 2026, Senator Rick Scott sent a letter to the Department of Health and Human Services, National Institutes of Health, and Food and Drug Administration, urging a review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approvals. He highlighted concerns about national security, American jobs, and patient safety, particularly referencing Bioheng, a China-based company with alleged CCP links, which had received expedited regulatory benefits in the U.S.
On January 29, 2026, Senator Rick Scott introduced the CLEAR LABELS Act, aiming to add country-of-origin labeling requirements to the U.S. prescription drug supply chain. This legislation seeks to enhance transparency by disclosing the original manufacturers of generic drugs and their active pharmaceutical ingredients, addressing concerns about foreign manufacturing, particularly in China and India.
On March 11, 2026, Chairman Rick Scott led a hearing titled 'Foreign Dependence: How China Captured America’s Drug Supply' to examine China's dominance in pharmaceutical manufacturing and its implications for U.S. national security and public health. The hearing emphasized the need for transparency and the importance of the CLEAR LABELS Act in addressing these concerns.
On March 23, 2026, Chairman Rick Scott and Ranking Member Kirsten Gillibrand highlighted their bipartisan CLEAR LABELS Act in an interview, emphasizing the need for country-of-origin labeling for prescription medicines to inform Americans about the origins of their medications.
On March 19, 2026, Senator Rick Scott sent a letter to the heads of the Department of Health and Human Services, National Institutes of Health, and Food and Drug Administration, urging a review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approvals. He highlighted concerns about national security, American jobs, and patient safety, specifically mentioning the China-based company Bioheng, also known as Imviva, which had received authorization to proceed under an Investigational New Drug application and was granted Regenerative Medicine Advanced Therapy designation and priority review.
On March 11, 2026, Chairman Rick Scott led a hearing titled 'Foreign Dependence: How China Captured America’s Drug Supply' to examine China's dominance in pharmaceutical manufacturing and its impact on the U.S. drug supply chain. During the hearing, he highlighted the bipartisan CLEAR LABELS Act, which aims to improve transparency by requiring clear disclosure of where medicines are manufactured.
On January 29, 2026, Senator Rick Scott introduced the CLEAR LABELS Act, legislation aimed at increasing transparency in the pharmaceutical supply chain by requiring country-of-origin labeling for prescription drugs. This initiative seeks to inform consumers about the sources of their medications and address concerns over foreign involvement in drug manufacturing.
Assessments
The promised action was to call for a comprehensive review, not necessarily to secure completion of the review. Evidence shows that on March 19, 2026, Senator Rick Scott sent formal letters to HHS, NIH, and FDA urging a review of CCP involvement in U.S. clinical trials and drug approval processes, with specific concerns about Bioheng/Imviva. Related oversight hearing activity and drug-supply transparency legislation further support that he materially pursued the issue during his current Senate term. Because the core promised act was the call itself, this counts as delivered in the same term.
Rick Scott made multiple, substantive legislative and oversight efforts in line with his campaign promise—introducing the CLEAR LABELS Act to increase transparency about drug origins and formally calling for a review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approvals. While these actions demonstrate serious intent and follow-through, they fall short of achieving a comprehensive review as an accomplished policy or executive action. No evidence indicates that a full and official comprehensive government review was completed or formally launched; the actions taken amount to hearings, calls for reviews, and the promotion/introduction of legislation, not definitive outcomes.
Rick Scott actively called for a comprehensive review of the Chinese Communist Party's involvement in U.S. clinical trials and drug approval processes, including sending formal letters to federal agencies, holding a relevant Senate hearing, and introducing legislation (the CLEAR LABELS Act) to increase transparency and oversight. However, while these actions show serious legislative and oversight efforts consistent with the promise, there is no evidence of a completed, government-wide comprehensive review as specified in the original promise. The efforts were substantial but came up short of full delivery.